The economics of the NHS cancer drugs fund

被引：0
|
作者：
Alan Maynard
Karen Bloor
机构：
[1] University of York,Department of Health Sciences
来源：
Applied Health Economics and Health Policy | 2011年 / 9卷 / 3期
关键词：
Multiple Sclerosis; Political Advantage; Cancer Drug Fund; Maximum Health Gain; Preferential Funding;
D O I：
10.2165/11585750-000000000-00000
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：137 / 138
页数：1
相关论文
共 50 条
  • [41] THE IMPACT OF CANCER DRUGS FUND REFORMS ON REIMBURSEMENT OF ONCOLOGY DRUGS IN THE UK
    Macaulay, R.
    Dave, K.
    Walsh, S. C.
    VALUE IN HEALTH, 2017, 20 (09) : A461 - A461
  • [42] TOP-UP INSURANCE TO FUND THE NHS? Should we emulate the French system to fund the NHS?
    Maynard, Alan
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
  • [43] HEALTH ECONOMICS IN THE NHS
    JENNINGS, M
    BRITISH MEDICAL JOURNAL, 1993, 306 (6869): : 68 - 68
  • [44] The Economics of a ‘Liberated’ NHS
    Nancy J. Devlin
    PharmacoEconomics, 2010, 28 : 1075 - 1078
  • [45] The Economics of a 'Liberated' NHS
    Devlin, Nancy J.
    PHARMACOECONOMICS, 2010, 28 (12) : 1075 - 1078
  • [46] Economics of PFI in the NHS
    Reeves, C
    BRITISH MEDICAL JOURNAL, 1999, 319 (7203): : 191 - 191
  • [47] THE ECONOMICS OF FUND RAISING
    STEINBERG, R
    TAKING FUND RAISING SERIOUSLY: ADVANCING THE PROFESSION AND PRACTICE OF RAISING MONEY, 1991, : 239 - 256
  • [48] The Cancer Drugs Fund in Practice and Under the New Framework
    Celia Sabry-Grant
    Kinga Malottki
    Alexander Diamantopoulos
    PharmacoEconomics, 2019, 37 : 953 - 962
  • [49] UK Cancer Drugs Fund to reassess 42 agents
    Cagney, Hannah
    LANCET ONCOLOGY, 2015, 16 (01): : E8 - E8
  • [50] OUT WITH THE OLD AND IN WITH THE NEW: THE EVOLUTION OF THE CANCER DRUGS FUND
    Doolub, N.
    Gupta, S.
    Lohmann, S.
    Khogeer, B.
    Grosvenor, A.
    VALUE IN HEALTH, 2019, 22 : S493 - S493
12345